Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Nello Salesi"'
Autor:
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D’Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D’Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Saccà, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnarò, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto, Patrizia Vici
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this
Externí odkaz:
https://doaj.org/article/8be0edebe30b47389bcf83b804b70b94
Autor:
Angela Maione, Nicola Tinari, Paola Pinnarò, Enzo Maria Ruggeri, Isabella Sperduti, Olivia Bacciu, Emanuela Risi, Icro Meattini, Federica Tomao, Luca Marchetti, Nicola D’Ostilio, Patrizia Vici, Lorenza Landi, Giuseppina Sarobba, Lucia Mentuccia, Elisabetta Landucci, Emilio Bria, A.F. Scinto, Gennaro Ciliberto, Laura Pizzuti, Elena Fiorio, Andrea Michelotti, Ida Paris, Simonetta Stani, Antonio Russo, Clara Natoli, Rosa Saltarelli, Alessandra Cassano, Paolo Marchetti, Maria Agnese Fabbri, Daniele Marinelli, Ferdinando Riccardi, Mauro Minelli, Corrado Ficorella, Anna Ceribelli, Maria Rosaria Valerio, Maddalena Barba, Jennifer Foglietta, Maria Mauri, Teresa Gamucci, Luca Moscetti, Beatrice Taurelli Salimbeni, Fabio Pelle, Daniele Santini, Andrea Botticelli, Vito Lorusso, Mirco Pistelli, Giacomo Barchiesi, Francesco Giotta, Eriseld Krasniqi, Antonino Grassadonia, Simone Scagnoli, Valentina Sini, Katia Cannita, Flavia Cavicchi, Michele De Tursi, Mimma Raffaele, Marco Mazzotta, Sonia Cappelli, Paola Scavina, Francesca Sofia Di Lisa, Giuliana D’Auria, Armando Orlandi, Marcello Maugeri-Saccà, Federico Cappuzzo, Claudio Botti, Nello Salesi, Lorenzo Livi, Beatrice Fratini, Giulia Bon, Silverio Tomao, Giuseppe Sanguineti, Enzo Veltri, Domenico Corsi, Enrico Cortesi, Rossana Berardi, Laura Iezzi, Rosalinda Rossi, Giuseppe Tonini, Elisabetta Maria Capomolla
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2782b71f4025d05ebb26120f95a63047
http://hdl.handle.net/10447/558103
http://hdl.handle.net/10447/558103
Autor:
Armando Orlandi, Luisa Carbognin, Laura Pizzuti, Paolo Marchetti, Nello Salesi, G. D'Auria, Giuseppe Tonini, Alessandra Cassano, A. Botticelli, Eriseld Krasniqi, Alessandra Fabi, Simone Scagnoli, Teresa Gamucci, A. Fabbri, Mauro Minelli, Patrizia Vici, Antonio Astone, Ilaria Portarena, Michela Roberto, Ida Paris, Francesco Pantano, Paola Scavina
Publikováno v:
Cancers, Vol 13, Iss 332, p 332 (2021)
Cancers
Cancers
Simple Summary The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy have remarkably improved the outcome of patients with HR+ advanced breast cancer. However, some poi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c286062b6dec3c8b400787e8e93036fa
http://hdl.handle.net/10807/191985
http://hdl.handle.net/10807/191985
Autor:
Giampiero Candeloro, Antonio Lugini, Francesco Giotta, Valentina Magri, Giovanni Scognamiglio, Patrizia Zucchinelli, Gennaro Gadaleta-Caldarola, Nello Salesi, Mirco Pistelli, Pietro Del Medico, Salvatore Pisconti, Guido Giordano, Maria Tedeschi, Alessio Schirone, Marta Mandarà, Giovanna Masci, Luigi Acito, Rossana Gueli, Anna Rizzi
Publikováno v:
The Oncologist. 21:1298-1305
Background. Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f0bd1a25f2e726f810b8785c8c8bed
https://doi.org/10.1634/theoncologist.2016-0022
https://doi.org/10.1634/theoncologist.2016-0022
Autor:
DE CESARE, Alessandro, DI FILIPPO, Annalisa Romina, DI CRISTOFANO, Claudio, Nello, Salesi, Piero, Francioni, Martina, Spaziani, Picchio, Marcello, Spaziani, Erasmo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3686::1710217831cda17cd82b0e82e51245b2
http://hdl.handle.net/11573/1173101
http://hdl.handle.net/11573/1173101
Autor:
Giuseppe Tonini, Alessandra Fabi, Andrea Michelotti, A. Vaccaro, Isabella Sperduti, Teresa Gamucci, Nello Salesi, Ilaria Ferrarini, Luigi Di Lauro, Enzo Veltri, E. Landucci, Laura Pizzuti, Luca Moscetti, Paolo Marchetti, Valentina Sini, Patrizia Vici, Lucia Mentuccia, Ida Pavese
Publikováno v:
Journal of Cancer
Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease. Objectives: This multicenter observational retrospective study was p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b00e50784e94b9f34e7652e2f4a1c66d
http://europepmc.org/articles/PMC3982178
http://europepmc.org/articles/PMC3982178
Autor:
Matthew Turner, Maria Sofia Rosati, Helen Barker, Karl Verpoort, Hans Tesch, Samir G. Agrawal, Nello Salesi, Nils Wilking, Pere Gascón, Michael Muenzberg
Publikováno v:
Supportive Care in Cancer
Biosimilars are similar, but non-identical, versions of existing biological drugs for which patents have expired. Despite the rigorous approval process for biosimilars, concerns have been expressed about the efficacy and safety of these products in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bb24ef6019ca5e2de93c54e09727cc
https://doi.org/10.1007/s00520-013-1911-7
https://doi.org/10.1007/s00520-013-1911-7
Publikováno v:
Future Oncology. 8:625-630
Aims: A biosimilar medicine is one with proven similarity to a reference biological product for which the patent has expired and whose active ingredient is produced or derived from a living organism. Recombinant granulocyte colony-stimulating growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52450a225aed5d21e0d070b5dfc0b909
https://doi.org/10.2217/fon.12.32
https://doi.org/10.2217/fon.12.32
Autor:
A. M. Cianciulli, Francesco Cognetti, Mariangela Ciccarese, Alessandra Felici, Armando Carpino, Nello Salesi, Paolo Carlini, Paola Papaldo, Marcella Mottolese, Diana Giannarelli, Alessandra Fabi, Isabella Sperduti, Vito Lorusso, Gianluigi Ferretti
Publikováno v:
Cancer Chemotherapy and Pharmacology. 57:615-623
Background: The aim of the study was to assess the toxicity profile, activity in terms of response rate, time to progression, overall survival, and quality of life of pegylated liposomal doxorubicin (PLD) and gemcitabine combination in chemo-naive an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4e209cab94995d873ea16cc96b8557
https://doi.org/10.1007/s00280-005-0116-2
https://doi.org/10.1007/s00280-005-0116-2
Autor:
Emilio Bria, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Andrea Michelotti, Michele Milella, Alessandra Fabi, Francesco Cognetti, Nicola Cresti, Andrea Alimonti, Gianluigi Ferretti, Manuela Pellegrini, Paola Papaldo, Sergio Ricci, Enzo Maria Ruggeri, Nello Salesi
The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43f1796ee37d1eb5dfe820bcb2e674c
http://hdl.handle.net/11562/873831
http://hdl.handle.net/11562/873831